January 8, 2024 12:49 PM EST
News Briefing

Sen­ti Bio cuts 37% of staff; Evotec pock­ets $25M mile­stone from BMS; No­var­tis buys San­Reno

Amber Tong

Ayisha Sharma

News Reporter

Plus news about Ory­zon Ge­nomics, Cu­mu­lus On­col­o­gy, Cure­Vac, Ori­on, Glykos Fin­land, Ra­di­ance Bio­phar­ma, Bio­cy­to­gen, Mark­er Ther­a­peu­tics and Hill­e­Vax:

Sen­ti Bio will lay off 37% of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times